C-type lectin domain family 3 member B (CLEC3B) inhibits triple-negative breast cancer chemoresistance via inducing ferroptosis.

ABSTRACT:

Background and aims

Cisplatin is one of effect chemotherapeutic drugs for triple-negative breast cancer (TNBC). However, cisplatin chemoresistance often generate in a notable proportion of TNBC patients, leading therapeutic failure. Thus, identification of key regulatory mechanisms for chemoresistance is important. Here, we aimed to study the functions and regulatory mechanisms of CLEC3B in cisplatin chemoresistance in TNBC.

Methods

MTT assay, colony formation assay and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay were employed to investigate the role of CLEC3B in cisplatin (CDDP) resistance in TNBC. Fe2⁺ Current assay and MDA level assay were used to determine CLEC3B's role in ferroptosis. Co-Immunoprecipitation was used to determine

SUBMITTER: Peng L 

PROVIDER: S-EPMC12326693 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature